Abstract
An increased expression of stromal platelet-derived growth factor receptor beta (PDGFRβ) has been associated with a poor prognosis in several solid tumor types. However, the prognostic relevance of PDGFRβ in NSCLC remains unclear. Since general PDGFRβ expression patterns do not reflect active PDGFRβ-signaling, it is likely that the activation status of the receptor would represent a more robust biomarker. The aim of this study is therefore to develop an in situ assay to detect activated PDGFRβ and to investigate its clinical relevance and prognostic potential for NSCLC patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
